Real world Evidence with Palbociclib in HR+/HER2- MBC in Indian population

Real world Evidence with Palbociclib in HR+/HER2- MBC in Indian population The combination of cyclin dependent kinase 4/6 inhibitors with endocrine therapy is the standard therapy in hormone receptor positive HER-2 negative metastatic breast cancer (HR+/HER2− MBC). Several randomized trials have shown the benefits of this combination, however, real world evidence in the Indian patients […]

CDK-4/6 inhibitors for the treatment of HR+/HER2 – advanced/metastatic breast cancer

Breast Cancer / Wembrace

CDK-4/6 inhibitors for the treatment of HR+/HER2 – advanced/metastatic breast cancer CDK-4/6 inhibitors for the treatment of HR+/HER2 The combination of cyclin dependent kinase 4/6 inhibitors with endocrine therapy is the standard therapy in hormone receptor positive HER-2 negative metastatic breast cancer (HR+/HER2− MBC). Several randomized trials have shown the benefits of this combination. Hormone

CDK-4/6 inhibitors for the treatment of HR+/HER2 – advanced/metastatic breast cancer Read More »